AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03140852 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Mind Over Matter; Healthy Bowels, Healthy Bladder
Description: This three-session workshop is based on proven principles of behavior change addressing urinary and bowel continence self-management and health education and has been developed specifically for administration to women age 50 and older in senior centers.
Study NCT03140852 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mind Over Matter; Healthy Bowels, Healthy Bladder
Description: This three-session workshop is based on proven principles of behavior change addressing urinary and bowel continence self-management and health education and has been developed specifically for administration to women age 50 and older in senior centers.
Study NCT03269331 — intervention group
Intervention type: BEHAVIORAL
Intervention: CTEP EBP Immersion
Description: 36 continuing ed credits, virtual library access, collaboration with expert mentors
Study NCT04145453 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention genotype personalized nutritional recommendations
Description: Participants will receive personalized nutritional recommendations to increase fruit and vegetables consumption. Information about genotype will be given at the beginning of study
Study NCT04145453 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Control Group 1 personalized nutritional recommendations
Description: Participants will receive genotype personalized nutritional recommendations to increase fruit and vegetables consumption. Information about genotype will be given at the end of study
Study NCT04145453 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control Group 2 general nutritional recommendations
Description: Participants will receive general nutritional recommendations to increase fruit and vegetables consumption
Study NCT00658021 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subcutaneous injection, twice a day
Study NCT00658021 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exenatide
Description: Subcutaneous injection, 5 µg, twice a day
Study NCT00658021 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exenatide
Description: Subcutaneous injection,10 µg, twice a day
Study NCT04016961 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: AAT - Dog
Description: therapy dog added to inpatient PT and OT session
Study NCT04016961 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: TAU - No Dog
Description: PT and OT as usual without the addition of therapy dog
Study NCT02936453 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Device implantation
Description: * Implantation of Specify 5-6-5 lead or Go-2 lead in epidural space~* Implantation of Activa RC neurostimulator
Study NCT03525925 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Given PO
Study NCT03525925 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT03525925 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV
Study NCT03954990 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: 4 tablets
Study NCT03496441 — intervention group
Intervention type: OTHER
Intervention: Fecal sample collection for analysis
Description: Fecal sample analysis will consist of the following procedure : Microbial DNA extraction, amplicon library construction, sequencing and analysis; Clustering MiSeq reads into operational taxonomic units (OTUs); Iron and heme measurements in the samples.
Study NCT03504397 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: zolbetuximab
Description: Zolbetuximab will be administered as a minimum 2-hour IV infusion.
Study NCT03504397 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo will be administered as a minimum 2-hour IV infusion.
Study NCT03504397 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Description: Oxaliplatin will be administered as a 2-hour IV infusion
Study NCT03504397 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: oxaliplatin
Description: Oxaliplatin will be administered as a 2-hour IV infusion
Study NCT03504397 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: folinic acid
Description: Folinic acid will be administered as a 2-hour IV infusion.
Study NCT03504397 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: folinic acid
Description: Folinic acid will be administered as a 2-hour IV infusion.
Study NCT03504397 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Description: Fluorouracil will be administered as IV bolus over 5-15 minutes and continuous IV infusion over 46-48 hours.
Study NCT03504397 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: fluorouracil
Description: Fluorouracil will be administered as IV bolus over 5-15 minutes and continuous IV infusion over 46-48 hours.
Study NCT03341819 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Total knee arthroplasty
Description: A surgical procedure in which parts of the knee joint are replaced with artificial parts (prostheses)
Study NCT03341819 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Total knee arthroplasty
Description: A surgical procedure in which parts of the knee joint are replaced with artificial parts (prostheses)
Study NCT03341819 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Urinary Catheterization
Description: Urinary catheterization is a latex, polyurethane, or silicone tube known as a urinary catheter is inserted into a patient's bladder via the urethra. Catheterization allows the patient's urine to drain freely from the bladder for collection.
Study NCT00319982 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diltiazem
Description: Sustained release formulation titrated to a target dose of 360 mg daily, or a maximum of 5 mg/kg/day in pediatric subjects for the duration of the study period
Study NCT00319982 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo comparator (double-blind allocation of study medication)
Study NCT00463242 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Agomelatine
Description: Either 25 mg or 50 mg agomelatine orally once daily
Study NCT00463242 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paroxetine
Study NCT00463242 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT00788294 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: tanezumab
Description: Drug solution given intravenously only once at dose of 10 mg
Study NCT03974932 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: Analgesic.
Study NCT00788294 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: tanezumab
Description: Drug solution given subcutaneously only once at dose of 5 mg.
Study NCT00788294 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: tanezumab
Description: Drug solution given subcutaneously only once at dose of 10 mg.
Study NCT02594735 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Abatacept
Description: Study participation will consist of a screening visit and 5 protocol visits over six months (week 0, week 6, week 12, week 18, and week 24) for each subject, and phone follow-up (week 2, week 4, week 8, week 10, week 14, week 16, week 20, and week 22). At Visit 1, which will be treatment initiation, eligible subjects will be instructed on the use and side effects of subcutaneous abatacept and will be started on the study drug (abatacept 125 mg SQ weekly for subjects with body weight ≥ 50 KG or abatacept 87.5mg SQ for subjects with body weight \< 50 KG).
Study NCT01318655 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NKTR-118
Description: Tablet, Oral, Once daily
Study NCT01318655 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablet, Oral, Once daily
Study NCT00788294 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: tanezumab
Description: Drug solution given subcutaneously only once at dose of 19 mg.
Study NCT00678041 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitrofurantoin
Description: nitrofurantoin 100mg to be taken daily while performing clean intermittent self-catheterization (CISC) and for three more days after stopping CISC
Study NCT00678041 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsule to be taken daily while performing clean intermittent self-catheterization (CISC) and for three more days after stopping CISC
Study NCT00643565 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard chemotherapy
Description: As prescribed
Study NCT00643565 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard chemotherapy
Description: As prescribed
Study NCT03974932 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib
Description: NSAID.
Study NCT03974932 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: +/- Bupivacaine HCl
Description: Local anesthetic.
Study NCT00643565 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab [Avastin]
Description: 7.5 mg/kg iv on day 1 of 9 x 3-week cycles, followed by 5 mg/kg iv on days 1 and 15 of each 4-week cycle
Study NCT00102518 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aripiprazole
Description: 2 to 30 mg/day orally (2, 5, 10, 15, 20, 25, or 30 mg/day); tablets in strengths of 2, 5, 10, and 15 mg were used to achieve desired doses
Study NCT03816514 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SpHb monitoring
Description: Noninvasive, continuous pulse oximetry-based hemoglobin (SpHb) monitoring
Study NCT03816514 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional management
Description: Conventional management without SpHb monitoring
Study NCT03111914 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Dual Energy Computed Tomography
Description: The subject's diagnostic scan will be preceded by a not clinically indicated non enhanced dual energy scan. The overall radiation dose to the patient for the first and second acquisition will be twice the radiation dose of a conventional CT of the chest, abdomen and pelvis. The non enhanced dual energy scan will be repeated during a clinical follow-up after the subject's first three months of enrollment and at a clinical follow-up after six months of enrollment.~The clinically-indicated, contrast-enhanced diagnostic scan will be performed according to standard of care.
Study NCT02569112 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: multipolar RF, varipulse
Description: Multi-polar Radio frequency (RF) technology combining pulsed electro magnetic fields (PEMF) and mild suction stimulation (varipulse).
Study NCT02569112 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: cryolipolysis
Description: Cryolipolysis technology uses the sensitivity of fat cells to cold injury, causing them to freeze and undergo cellular apoptosis.
Study NCT02569112 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: cryolipolysis
Description: Cryolipolysis technology uses the sensitivity of fat cells to cold injury, causing them to freeze and undergo cellular apoptosis.
Study NCT01592305 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: atazanavir
Description: multiple oral doses
Study NCT01592305 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: danoprevir
Description: multiple oral doses
Study NCT00106080 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Audit and Feedback
Description: Intervention patients and clinicians received a one-page patient-specific individualized summary, based on questionnaire responses, to stimulate conversations.
Study NCT01592305 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ritonavir
Description: multiple oral doses
Study NCT01592305 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tenofovir disoproxil fumarate
Description: single oral doses
Study NCT03584984 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Mixture of Autogenous bone & Anorganic Bovine Bone (ABB)
Description: Filling the socket with Mixing of autogenous bone graft and anorganic bovine bone in a 50:50 ratio
Study NCT03584984 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Anorganic Bovine Bone (ABB)
Description: Filling the socket with Anorganic bovine bone graft material only
Study NCT03974932 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Luer Lock Applicator
Description: Applicator for instillation.
Study NCT02861066 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-based Intervention
Description: MBI will be delivered in group format, 120 minutes per week, for 6 consecutive weeks with 10-20 participants per group.
Study NCT04034771 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melatonin 10 MG Oral Tablet
Description: Melatonin tablets
Study NCT04034771 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: propofol amp
Study NCT04034771 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: propofol amp
Study NCT04034771 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo oral tablet
Description: sugar pill manufactured to mimic melatonin tablets
Study NCT05035966 — intervention group
Intervention type: OTHER
Intervention: Plasma β-amyloid 40 and 42 concentration
Description: Plasma β-amyloid 40 and 42 concentrations were simultaneously measured by validated assay platforms from Meso Scale Discovery (MSD; Rockville, MD, USA).
Study NCT04457752 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Dual Layer Amniotic Membrane (DLAM). Artacent®
Description: Artacent® is a double layer of dehydrated amniotic membrane. The amnion is harvested from human placenta obtained during planned Caesarean sections. Tides Medical uses a proprietary process to clean and decellularize the amniotic membrane. The amnion is then folded into a bi-layer with the stromal sides facing outward. The dual layer is dried and cut into various sizes. In the final step the DLAM is terminally sterilized.~Atracent®, like all other placental-derived products, is FDA cleared for homologous use through the 361 pathway. It is indicated for non-healing ulcers applied to a debrided, clean and uninfected ulcers.
Study NCT05025995 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Serious health game
Description: Serious health game
Study NCT02330926 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: standard care
Study NCT02330926 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: standard care
Study NCT02330926 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: nutritional supplements and advice
Study NCT02330926 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: home-based self-assisted exercise program
Study NCT02330926 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Study NCT01248260 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Folic Acid
Description: 4mg of higher strength folic acid once a day until delivery
Study NCT01448317 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alirocumab (Solution)
Description: Pharmaceutical form: solution~Route of administration: subcutaneous
Study NCT01448317 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alirocumab (Lyophilized formulation)
Description: Pharmaceutical form: lyophilized formulation~Route of administration: subcutaneous
Study NCT01448317 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (Solution)
Description: Pharmaceutical form: solution~Route of administration: subcutaneous
Study NCT01448317 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (Lyophilized formulation)
Description: Pharmaceutical form: lyophilized formulation~Route of administration: Subcutaneous
Study NCT00603850 — intervention group
Intervention type: DEVICE
Intervention: ForeseeHome
Description: human factor
Study NCT01056419 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Total Thyroidectomy
Description: Total thyroidectomy within 6 months after the appearance of the symptoms of ophthalmopathy
Study NCT01056419 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propylthiouracil
Description: 150-600 mg in two-three divided doses
Study NCT02509676 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: stretching exercise
Description: dynamic stretching exercises with 5 repetitions, each lasting 45 seconds, for 5 days a week and 3 times a day
Study NCT05007223 — intervention group
Intervention type: DRUG
Intervention: Doxycycline
Description: 200mg/day for 28 days(Given doxycycline to patients with Hailey-Hailey disease)
Study NCT03446989 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Case management
Description: completing assessment, detecting the presence of RA complications, consultation about taking medications and exercise, education for patients and their family, assist in formulating a management, and providing a basis for continuing care for each patient. Additionally, the management plan was rationally modified in accordance with the individualized therapeutic alliance of the patient, his/her family, the physician or other members of the medical team.
Study NCT02573337 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Emervel Classic Lidocaine
Description: Treatment of wrinkles and folds
Study NCT02573337 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Emervel Deep Lidocaine
Description: Treatment of wrinkles and folds
Study NCT00050622 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylphenidate 0.15 mg/kg
Description: 0.15 m/kg/dose immediate-release methylphenidate
Study NCT00050622 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Low-Intensity BMOD
Description: Lower-intensity behavioral treatment package.
Study NCT00050622 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylphenidate 0.3 mg/kg
Description: 0.3 mg/kg/dose immediate-release methylphenidate
Study NCT00050622 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Study NCT00050622 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00050622 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylphenidate 0.6 mg/kg
Description: 0.3 mg/kg/dose immediate-release methylphenidate
Study NCT00050622 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: High Intensity BMOD
Description: Comprehensive high-intensity Summer Treatment Program (STP)
Study NCT03483116 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RV3-BB
Description: Oral administration
Study NCT03483116 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral administration
Study NCT01577784 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pazopanib
Description: 800 mg / day of pazopanib in monotherapy.
Study NCT01592006 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2a
Description: Patients will be treated with pegylated interferon alfa-2a (Pegasys®) 180 mcg SQ per week for 12 weeks, followed by pegylated interferon alfa-2a (Pegasys®) and ribavirin for another 36 weeks. Patients will be assessed at periodic intervals for safety and adverse effects. Following completion of therapy, patients will be followed for another 24 weeks to determine sustained response.
Study NCT01592006 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Patients will be given ribavirin 600-1200 mg PO per day for 12 weeks, followed by pegylated interferon alfa-2a (Pegasys®) and ribavirin for another 36 weeks. Patients will be assessed at periodic intervals for safety and adverse effects. Following completion of therapy, patients will be followed for another 24 weeks to determine sustained response.
Study NCT01592006 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: telaprevir
Description: Patients will be given telaprevir 750 mg tid (Incivek®) for 12 weeks, followed by pegylated interferon alfa-2a (Pegasys®) and ribavirin for another 36 weeks. Patients will be assessed at periodic intervals for safety and adverse effects. Following completion of therapy, patients will be followed for another 24 weeks to determine sustained response.
Study NCT04348994 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Non-ablative thermal-only Er:YAG laser therapy
Description: Each patient will receive 3 sessions of Er:YAG laser treatment for SUI (IncontiLase®).~Single-session treatments will be offered to patients after 18, 24 and 30 months following the initial three sessions.
Study NCT02789826 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic gastrectomy
Description: Patients allocated to the 'laparoscopic gastrectomy' arm will receive gastrectomy via laparoscopy.
Study NCT02789826 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open gastrectomy
Description: patients allocated to the 'Open gastrectomy' group will receive gastrectomy via laparotomy